Robin LaChapelle
Known title: Chief Operating OfficerCIK: 0002009136
Associated companies
Transaction History
| AVBP | ▲ Buy | Option Exercise | 2,050 | $5K | 7/11/2025 | View on chart |
| AVBP | ▲ Buy | Option Exercise | 2,600 | $6K | 7/11/2025 | View on chart |
| AVBP | ▲ Buy | Option Exercise | 6,503 | $15K | 7/11/2025 | View on chart |
| AVBP | ▲ Buy | Option Exercise | 2,700 | $17K | 9/19/2024 | View on chart |
| AVBP | ▲ Buy | Option Exercise | 2,867 | $7K | 9/19/2024 | View on chart |
| AVBP | ▲ Buy | Option Exercise | 7,164 | $16K | 9/19/2024 | View on chart |
| AVBP | ▲ Buy | Option Exercise | 2,471 | $6K | 9/19/2024 | View on chart |
| AVBP | ▲ Buy | Option Exercise | 12,364 | $45K | 9/19/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
AVBP: First Patient Dosed in Phase 1 Dual-Target ADC Trial
ArriVent BioPharma reported that the first patient has been dosed in its Phase 1 study of the dual‑target antibody‑drug conjugate ARR‑002 for ovarian and endometrial cancer. The trial uses a tetravalent design that targets both MUC16 and NaPi2b. BTIG reaffirmed its rating on the company and kept its $29 price target. The news arrives while the stock trades near recent support and shows an RSI in oversold territory.
AVBP: First Patient Dosed in Phase 1 Dual-Target ADC Trial. ArriVent BioPharma reported that the first patient has been dosed in its Phase 1 study of the dual‑target antibody‑drug conjugate ARR‑002 for ovarian and endometrial cancer. The trial uses a tetravalent design that targets both MUC16 and NaPi2b. BTIG reaffirmed its rating on the company and kept its $29 price target. The news arrives while the stock trades near recent support and shows an RSI in oversold territory.